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Purpose: To investigate the efficacy, safety, and tolerability of oro-dispersible film (ODF) formulation of mirodenafil 50 mg and 100 
mg for the treatment of patients with erectile dysfunction (ED) in Korea.
Materials and Methods: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 129 subjects was per-
formed. Subjects were randomized to either placebo or mirodenafil ODF 50 mg or 100 mg to be taken in an “on demand” manner 
for 8 weeks. The primary efficacy variable was the International Index of Erectile Dysfunction (IIEF)-5 questionnaire. The secondary 
efficacy variables comprised Sexual Encounter Profile questions 2 and 3 (SEP2 and SEP3), the Global Assessment Question (GAQ), 
and the Life Satisfaction Checklist (LSC).
Results: IIEF-5 was significantly increased in all groups after treatment. However, compared to the placebo group, only the mirode-
nafil ODF 100 mg group showed a significant difference. SEP2 and SEP3 were increased in both mirodenafil groups; however, the 
increase was not statistically significant for SEP2. In terms of GAQ and LSC, the mirodenafil ODF groups showed significant increases 
compared with the baseline. Most treatment-associated adverse events were mild and resolved spontaneously.
Conclusions: Mirodenafil ODF is an effective and well-tolerated agent for the treatment of patients with ED in Korea.
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Phosphodiesterase type 5 (PDE5) inhibitors dilate 
the corpora cavernosa of the penis, facilitating erection 
upon sexual stimulation, and are used in the treatment 
of erectile dysfunction (ED). PDE5 inhibitors prolong 
the action of cyclic guanosine monophosphateby inhib-
iting its degradation by the enzyme PDE5 [1].
The currently approved PDE5 inhibitors in South 
Korea include sildenafil, vardenafil, tadalafil, udenafil, 
avanafil, and mirodenafil. These PDE5 inhibitors have 
slight differences in efficacy, which are attributed to 
their individual characteristics, but are generally ex-
cellent therapies for ED [2]. Therefore, PDE5 inhibition 
has been established as first-line therapy for ED in the 
European Association of Urology and American Uro-
logical Association guidelines [3,4].
Mirodenafil (Mvix; SK Chemicals Life Science, 
Seongnam, Korea), developed in 2007 in Korea, is a 
second-generation PDE5 inhibitor. So far, it has been 
approved for use only in the Korean market. The phar-
macokinetic profile of mirodenafil is similar to that 
of sildenafil, but its selectivity for PDE5 is 10 times 
stronger than that of sildenafil [5]. To date, mirodenafil 
has shown excellent efficacy and safety in the clinical 
studies, regardless of the etiology or severity of ED [5-9].
Although PDE5 inhibitors are the most effective 
and widely used ED therapeutics, dropout rates are re-
ported to be between 11% and 57% [10]. The reasons for 
dropout include: abstinence for a long period of time 
before treatment, concerns about side effects, comor-
bidities with ED, drug cost, loss of sexual interest on 
the part of the patient or partner, and inconvenience 
or rejection of planned sexual activity.
Orally disintegrating formulations have been devel-
oped with the aim of improving adherence to treat-
ment with PDE5 inhibitors by providing a more conve-
nient form of administration. An orally disintegrating 
formulation is defined as a single layer or multilayer 
sheet of suitable materials. When administered, the pa-
tient does not need to drink water; with a little saliva, 
the formulation melts within a few minutes on the 
tongue [11].
Orally disintegrating formulations can make PDE5 
inhibitors available to patients who have difficulty 
with fluid intake owing to medical problems, such 
as renal impairment and congestive heart failure, or 
patients who have difficulty swallowing conventional 
tablet dosage forms owing to dysphagia. In South Ko-
rea, sildenafil, vardenafil, and tadalafil were developed 
as orally disintegrating formulations in the form of 
oro-dispersible film (ODF) or oro-dispersible tablet 
(ODT). The ODF formulation of mirodenafil was de-
veloped in December 2011 and is currently in clinically 
use.
In this clinical trial, we investigated the efficacy, 
safety, and tolerability of mirodenafil ODF 50 mg and 
100 mg for the treatment of patients with ED in Korea.
MATERIALS AND METHODS
1.  Ethics statement and description of study 
design
This double-blind, randomized, placebo-controlled, 
parallel-group, multicenter, phase IV study was con-
ducted at 16 centers in Korea in accordance with Good 
Clinical Practice and was consistent with the ethical 
principles of the Declaration of Helsinki (2013). Writ-
ten informed consent was obtained from each patient 
before enrolment in the study. All forms of the docu-
ments related to this clinical study, i.e., the protocol and 
the informed consent form, were approved by the rel-
evant institutional review board of the Pusan National 
University Hospital (IRB No. 1210-010-012).
Initially, eligible patients had a 4-week, treatment-
free run-in period during which the patients were re-
quired to have attempted intercourse on at least four 
separate days and have been unsuccessful in at least 
half of these attempts. Subsequently, the patients were 
randomly assigned to receive mirodenafil ODF 50 mg 
or 100 mg or placebo.
In this clinical study, block randomization was per-
formed in a manner that the proportion of subjects 
between the dosing groups was set to 1:1:1 for placebo: 
mirodenafil ODF 50 mg: mirodenafil ODF 100 mg in 
consideration of the appropriate block size. Subjects as-
signed to each administration group received the clini-
cal trial drug for 8 weeks and were instructed to visit 
the hospital after administration of the study drug for 
4 and 8 weeks (Fig. 1A).
2. Investigational drugs
The mirodenafil ODF contained 50 mg or 100 mg of 
mirodenafil in one sheet and was a white translucent 
rectangle. The placebo was a white translucent square 
film that did not contain mirodenafil but was other-
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wise indistinguishable from the mirodenafil ODF. The 
patients were instructed to take the investigational 
drug for 8 weeks in an ‘on demand’ or ‘as needed’ man-
ner, ~30 minutes before sexual intercourse, and to not 
exceed one dose per day during the trial.
3. Subjects
The inclusion criteria were as follows: men with a 
history of ED for at least 6 months according to the 
National Institutes of Health (NIH) Consensus State-
ment (inability to attain and/or maintain penile erec-
tion sufficient for satisfactory sexual performance); 
over 20 years of age; in a stable, monogamous rela-
tionship with a female sexual partner; and had failed 
>50% of at least four sexual attempts during the run-
in period.
Men with the following conditions were excluded 
from the study: penile anatomical defects, spinal cord 
injury, radical prostatectomy, and radical pelvic sur-
gery; a primary diagnosis of another sexual disorder; 
retinitis pigmentosa; uncontrolled diabetes mellitus 
(HbA1C >12%); proliferative diabetic retinopathy; se-
rum total testosterone level <2.5 ng/mL; serum prolac-
tin level >55 ng/mL; serum creatinine >2.5 mg/dL; ma-
jor uncontrolled psychiatric disorder; history of major 
hematological, renal, or hepatic abnormalities; recent 
(within the previous 6 months) history of cardiovas-
cular disease, stroke, or myocardial infarction, cardiac 
failure, unstable angina, life-threatening arrhythmia; 
and a history of alcoholism or substance abuse. In addi-
tion, patients were ineligible if they had been receiving 
regular treatment with nitrates, anticoagulants (except 
for low-dose aspirin), androgens, anti-androgens, cyto-
chrome P450 3A4 inhibitors, anticancer chemotherapy, 
or trazodone. Patients with a history of anaphylactic 
reaction to PDE5 inhibitors or unsuccessful use of 
sildenafil, vardenafil, tadalafil, udenafil, and avanafil 
or those who had taken other agents in a clinical trial 
within the previous month were excluded from the 
study. The concomitant use of any ED treatment was 
prohibited.
4. Outcome measures
The primary efficacy variable was a change in the 
score of the International Index of Erectile Dysfunction 
(IIEF)-5 questionnaire from the baseline. Secondary ef-
ficacy variables included changes in question 2 and 3 
of the Sexual Encounter Profile (SEP2: Were you able 
to insert your penis into your partner’s vagina? SEP3: 
Did your erection last long enough for you to have 
successful intercourse?) from baseline and patient re-
sponses to the Global Assessment Question (GAQ: Has 
the treatment you have been taking during the last 4 
weeks improved your erections?) and Life Satisfaction 
Checklist (LSC) [12]. The safety assessments included 
laboratory tests (hematology, clinical biochemistry, 
blood coagulation test, and urinalysis), vital signs (blood 
pressure and heart rate), physical examination, 12-lead 
electrocardiogram recordings, and patients’ reporting of 
adverse events.
5. Statistical analysis
Efficacy analysis was performed on the full analy-
sis set (FAS) population. The last-observation-carried-
forward imputation method was used for missing 
data. The repeated measures analysis of covariance 
(ANCOVA) method, using baseline characteristics as 
covariates, was used to evaluate the primary efficacy 
endpoints and all secondary endpoints, except for GAQ. 
Efficacy was calculated in comparison with the placebo 
group after assessment of the change from baseline at 
given points, including the end of treatment. Within 
each group, the changes from baseline in the primary 
efficacy endpoints and all secondary endpoints at a 
given point were assessed by repeated measures analy-
sis of variance (ANOVA), except for GAQ and LSC. 
Inter-group differences in the GAQ response rate were 
analyzed using a χ2 test or Fisher’s exact test. Statisti-
cal significance was accepted at the p<0.05 level.
In this clinical trial, the number of subjects was cal-
culated through the analysis of phase II and III clinical 
trials of 50 mg or 100 mg mirodenafil tablet. The anal-
ysis of the scores of the IIEF-5 domain, the primary 
efficacy endpoint of this clinical trial, using weighted 
averages and weighted variances, revealed that the 
mean±standard deviation was 8.67±6.43 in patients 
receiving mirodenafil tablet and 2.26±6.11 in patients 
receiving placebo [5,6]. With approximately 33 avalu-
able patients per group, this study had a power of ap-
proximately 90% at a significance level of 0.05. Allow-
ance for a 30% withdrawal rate required a total of 144 
randomized patients for the efficacy analysis, with 48 
patients per group. Statistical analyses were performed 




The patients’ demographic variables and the efficien-
cy data were analyzed in the FAS. All subjects who re-
ceived any amount of study drug and had at least one 
post-baseline safety assessment were included in the 
safety set, and the safety evaluation was performed on 
this set.
In total, 137 subjects were screened after they pro-
vided written consent to participate in the study. Eight 
subjects failed the screening procedures; consequently, 
129 subjects were randomized to receive 50 mg mirode-
nafil ODF, 100 mg mirodenafil ODF, or placebo (all n= 
43).
Of the 129 randomly assigned subjects, 127 subjects 
were administered the investigational drugs (safety 
set: 43 in the 50 mg mirodenafil group, 43 in the 100 
mg mirodenafil group, and 41 in the placebo group), 
and 120 of these completed the trial (40 subjects in 
each of the 50 mg mirodenafil, 100 mg mirodenafil, 
and placebo groups). During the 8 weeks of therapy, 9 
(7.0%) patients withdrew from the study: five subjects 
withdrew their consent (two in the 50 mg mirodenafil 
group, two in the 100 mg mirodenafil group, and one in 
the placebo group); three subjects committed a protocol 
violation (one subject each in the 50 mg mirodenafil, 
100 mg mirodenafil, and placebo groups) and were ex-
cluded; and one subject in the placebo group withdrew 
for unknown reasons (Fig. 1B).
1. Demographics
The demographic information and baseline charac-
teristics of the 126 subjects included in the FAS group 
are summarized in Table 1.
The mean age of the patients was 59.92±8.46 years, 
and the mean duration of ED was 4.26±3.56 years. At 
baseline, no clinically or statistically meaningful differ-
ences were found between the treatment groups with 
regard to demographic or clinical variables.
4 wk 0 wk 4 wk 8 wk
Placebo
Mirodenafil ODF 50 mg
Mirodenafil ODF 100 mg





















Fig. 1. Study schedule (A) and patient 
disposition (B). ODF: oro-dispersible film.
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2. Efficacy outcome variables
1)  International Index of Erectile 
Dysfunction-5
IIEF-5 increased significantly in all groups after 
treatment (p<0.0001 at both mirodenafil doses, p=0.0437 
in the placebo group). However, compared with the 
placebo group, only the 100 mg mirodenafil ODF group 
showed a significant difference (p=0.0256) (Fig. 2).
2)  Sexual Encounter Profile 2 (Were you able 
to insert your penis into your partner’s 
vagina?)
SEP2 increased significantly in all groups after 
Table 1. Demographic and baseline characteristics of patients (full analysis set)
Variable Mirodenafil ODF  
50 mg (n=43)
Mirodenafil ODF  
100 mg (n=42)
Placebo (n=41) Total (n=126)
Age (y)
   Patient (n) 43 42 41 126
   Mean (SD) 61.47 (6.86) 59.17 (9.40) 59.07 (8.93) 59.92 (8.46)
   Median 61.00 61.00 61.00 61.00
   Min, Max 45.00, 75.00 39.00, 73.00 35.00, 75.00 35.00, 75.00
   p-valuea 0.3392
Height (cm)
   Patient (n) 42 42 41 125
   Mean (SD) 169.41 (5.54) 171.22 (6.17) 169.53 (4.56) 170.06 (5.49)
   Median 169.00 170.00 169.00 169.80
   Min, Max 156.20, 180.00 161.20, 189.00 161.00, 180.00 156.20, 189.00
   p-valuea 0.2429
Weight (kg)
   Patient (n) 42 42 41 125
   Mean (SD) 70.20 (7.99) 71.30 (7.44) 70.45 (8.69) 70.65 (8.00)
   Median 70.00 70.00 71.00 70.00
   Min, Max 56.00, 90.30 56.70, 86.00 51.00, 96.20 51.00, 96.20
   p-valuea 0.8085
History of ED (y)b
   Patient (n) 43 42 41 126
   Mean (SD) 5.07 (4.58) 3.90 (2.65) 3.78 (3.03) 4.26 (3.56)
   Median 3.00 3.00 3.00 3.00
   Min, Max 1.00, 24.00 1.00, 11.00 1.00, 15.00 1.00, 24.00
   p-valuea 0.1839
Severity of ED (IIEF-5 score)
   Paitient (n) 43 42 41 126
   Mean (SD) 10.95 (3.80) 9.24 (4.22) 9.88 (4.13) 10.03 (4.08)
   Median 11.00 10.00 11.00 11.00
   Min, Max 1.00, 17.00 1.00, 17.00 1.00, 19.00 1.00, 19.00
   p-valuea 0.1470
Severity of ED, n (%)
   Severe (IIEF-5 score <11) 15 (34.88) 24 (57.14) 20 (48.78) 59 (46.83)
   Moderate (IIEF-5 score 11–16) 26 (60.47) 16 (38.10) 19 (46.34) 61 (48.41)
   Mild to moderate (IIEF-5 score 17–21) 2 (4.65) 2 (4.76) 2 (4.88) 6 (4.76)
   p-valuec 0.3044
ODF: oro-dispersible film, SD: standard deviation, Min: minimum, Max: maximum, ED: erectile dysfunction, IIEF-5: International Index of Erectile 
Function-5.
aDifference between the treatment groups (ANOVA). bHistory of ED (year)=year of diagnosis-year of consent+1. cDifference between the treat-
ment groups (Fisher’s exact test).
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treatment. However, there was no statistically signifi-
cant difference at either mirodenafil dose compared 
with the placebo group (Table 2).
3)  Sexual Encounter Profile 3 (Did your 
erection last long enough for you to have 
successful intercourse?)
SEP3 increased significantly in all groups after 
treatment. On comparing these changes with the pla-
cebo group, the differences in the mirodenafil ODF 50 
mg and 100 mg groups were statistically significant 
(p=0.0056, p=0.0432) (Table 2).
4)  Global Assessment Question (Has the 
treatment you have been taking during the 
last 4 weeks improved your erections?)
When the proportion of patients who responded posi-
tively to GAQ after treatment was compared with that 
in the placebo group, the differences in the mirodenafil 
ODF 50 mg and 100 mg groups were statistically sig-
nificant (p=0.0063, p=0.0018) (Table 2).
5) Life Satisfaction Checklist
After treatment, both the mirodenafil 50 mg and 100 
mg groups showed significant increases compared with 
the baseline (p=0.0036, p<0.0001). However, compared 
with the placebo group, these changes were not statis-
tically significant (Table 2).
3. Safety results
Safety was analyzed in 127 patients who received the 
trial drug (the safety set). The number of treatment-
emergent adverse events (TEAEs) was 7/43 (16.28%) in 
the 50 mg mirodenafil ODF group, 10/43 (23.26%) in the 
100 mg mirodenafil ODF group, and 5/41 (12.20%) in 
the placebo group. However, no serious adverse events 
occurred. The difference in the incidence of TEAEs 
among the groups during the clinical trial period was 
not statistically significant (Table 3).
DISCUSSION
The pharmacokinetic profile of mirodenafil is de-
scribed by a time to peak serum concentration (Tmax) 
of 1.25 hours, a half-life (T1/2) of 2.5 hours, and a half-
maximal inhibitory concentration (IC50) for PDE5 of 
0.34 nmoL/L; thus, it has a relatively high affinity (po-
tency) for PDE5 [5,13].
In phase II and III studies, treatment with mirode-
nafil 50 mg and 100 mg resulted in an increase of 
5.3–8.4 and 7.6–11.6 points in IIEF-5 or IIEF-EF, respec-
tively.
The results for SEP2 showed an increase of 27.72%–
43.4% and 37.3%–38.98% after treatment, respectively, 
and SEP3 showed an increase of  28.6%–44.9% and 
63.2%–67.33%, respectively. After treatment, the pro-
portion of  patients who moved to the category of 
normal erectile function, as indicated by IIEF, was 
17.3%–24.1% and 51.7%–62.2% in the mirodenafil 50 mg 
and 100 mg treatment groups, respectively [5-8,14]. The 
results of clinical studies conducted on patients with 
ED and specific concurrent diseases have also been re-
ported. Mirodenafil 100 mg increased IIEF-EF by 9.35 
and 9.3 points, respectively, in clinical trials conducted 
in patients with ED and hypertension or diabetes, re-
spectively. In these studies, SEP2 increased by 30.2% 
and 36.1%, respectively, and SEP3 increased by 55.3% 
and 61.8%, respectively. In the classification by IIEF-EF 
score, 40.7% and 32.7% of patients, respectively, moved 
to the category of normal erectile function after treat-
ment [7,8].
The main purpose of this phase IV study was to in-
vestigate the efficacy and safety of mirodenafil ODF in 
general patients with ED. The study utilized a double-
blind, randomized, placebo-controlled, parallel-group, 
multicenter design.
Orally disintegrating formulations, considered in-
novative drug delivery systems, can increase patient 



































Fig. 2. Effects of mirodenafil on the IIEF-5 score at 8 weeks after the 
start of treatment. ODF: oro-dispersible film, IIEF-5: International In-
dex of Erectile Function-5. *p=0.0256 vs. placebo.
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Table 2. Summary of primary and secondary outcomes before and after treatment
Variable Mirodenafil ODF 50 mg (n=43) Mirodenafil ODF 100 mg (n=42) Placebo (n=41)
IIEF-5 (full analysis set)
   Baseline 11.14±3.97 8.83±3.95 10.02±3.95
   Week 8 14.33±5.19 13.55±5.79 11.90±4.99
   Change 3.19±4.86 4.71±4.58 1.88±4.60
   p-value (RM  ANOVA) <0.0001 <0.0001 0.0437
   Difference vs. placebo p-value (RM ANCOVA) 0.0869 0.0256
SEP2  (full analysis set)
   Baseline 47.92±44.88 41.63±44.07 37.36±43.34
   Week 8 77.91±36.27 75.99±36.40 62.80±42.78
   Change 29.99±45.93 34.36±45.09 25.45±58.18
   p-value (RM ANOVA) <0.0001 <0.0001 0.0002
   Difference vs. placebo p-value (RM ANCOVA) 0.0902 0.0783
SEP3 (full analysis set)
   Baseline 6.35±14.06 8.39±20.21 7.59±22.51
   Week 8 49.81±41.80 49.60±39.77 31.71±39.54
   Change 43.46±38.25 41.22±41.63 24.12±48.42
   p-value (RM ANOVA) <0.0001 <0.0001 0.0003
   Difference vs. placebo p-value (RM ANCOVA) 0.0056 0.0432
Mirodenafil ODF 50 mg (n=40) Mirodenafil ODF 100 mg (n=37) Placebo (n=38)
GAQ (per-protocol set)
   Response rate 25 (62.50) 25 (67.57) 12 (31.58)
   Compare with placebo p-value (chi-square test) 0.0063 0.0018
Mirodenafil ODF 50 mg (n=43) Mirodenafil ODF 100 mg (n=42) Placebo (n=41)
LSC (full analysis set)
   Baseline 31.77±4.92 28.93±6.16 30.24±5.92
   Week 8 33.88±4.40 32.08±7.15 31.34±6.46
   Change 2.14±4.50 3.15±4.59 1.10±3.74
   p-value (paired t-test) 0.0036 <0.0001 0.0676
   Difference vs. Placebo p-value (ANCOVA) 0.1060 0.0608
Values are presented as mean±standard deviation or number (%).
ODF: oro-dispersible film, IIEF-5: International Index of Erectile Dysfunction-5, RM ANOVA: repeated measures analysis of variance, RM ANCOVA: 
repeated measures analysis of covariance, SEP: Sexual Encounter Profile, GAQ: Global Assessment Question, LSC: Life Satisfaction Checklist.
Table 3. Brief summary of TEAEs (safety analysis set)
Variable
Mirodenafil ODF  
50 mg (n=43)
Mirodenafil ODF  
100 mg (n=43)
Placebo (n=41) Total (n=127)
Number of subjects with TEAEs 7 (16.28) 10 (23.26) 5 (12.20) 22 (17.32)
   95% confidence interval 5.24–27.31 10.63–35.88 2.18–22.21 10.74–23.90
   p-value (chi-square test) 0.3981
Number of TEAEs 
   Mild 22 29 10 61
   Moderate   0   1   0   1
   Severe   0   0   0   0
Values are presented as number (%) or number only. 
TEAEs: treatment-emergent adverse events, ODF: oro-dispersible film.
https://doi.org/10.5534/wjmh.200157
8 www.wjmh.org
Studies on orally disintegrating formulations of 
sildenafil have been published. In the bioequivalence 
study of a sildenafil 100 mg ODF compared with the 
conventional film-coated 100 mg tablet administered to 
healthy male volunteers, the pharmacokinetic profiles 
were not significantly different and the incidence of 
adverse events was similar [11]. In the study conducted 
by Cocci et al [15], a sildenafil ODF had equivalent 
safety and effectiveness to the film-coated tablets 
but had better results in terms of overall satisfaction. 
These results suggest that the ODF can be used inter-
changeably with conventional film-coated formulations.
Orally disintegrating formulations provide an op-
portunity for ED treatment in patients who find it 
difficult to take conventional PDE5 tablets owing to 
specific diseases or condition. ED tends to coexist with 
chronic diseases, and patients with ED are often elder-
ly individuals who need to take various concomitant 
medications. Therefore, for patients with diseases such 
as renal impairment, congestive heart failure, nocturia, 
and dysphasia, a drug that does not require water pro-
vides the convenience of discreet administration [16-18].
A rapidly disintegrating ODT formulation of var-
denafil 10 mg was developed and is being marketed 
in South Korea, Europe, the United States, and other 
countries. Vardenafil 10 mg ODT has a pharmacoki-
netic profile similar to that of vardenafil film-coated 
tablets; however, it has greater bioavailability owing 
to significant drug absorption through the oral mucosa 
[19]. Although they are similar to orally disintegrat-
ing formulations, ODFs offer several advantages over 
ODTs. ODTs have problems related to hardness and 
friability during the processes of manufacture, stor-
age, handling, and administration, and there is also a 
risk of choking [16]. ODFs are thin and flexible, can 
be manufactured in a range of sizes and shapes, and 
are easily transported and stored. Owing to these ad-
vantages, it was reported that four out of five patients 
prefer orally disintegrating dosage forms over conven-
tional solid oral dosage forms [18].
In South Korea, ODFs of mirodenafil, tadalafil, and 
sildenafil are already used widely and are the primary 
treatment for patients with ED. However, no clinical 
studies on these ODFs have been published.
We believe this study is significant as it is the first 
report of a clinical trial on a mirodenafil ODF. In this 
study, the mean IIEF-5 scores were increased by 3.19 
and 4.71 in the mirodenafil ODF 50 mg and 100 mg 
treatment groups, respectively, after 8 weeks of treat-
ment. These increases were slightly lower than those 
reported in a previous study of mirodenafil conven-
tional tablets.
With regard to SEP2, the 50 mg and 100 mg mirode-
nafil ODF groups showed increases in the mean re-
sponse rate of 29.99% and 34.36%, respectively, after 
treatment. This was similar to the results of previous 
studies on mirodenafil conventional tablets [5-8]. With 
regard to SEP3, the 50 mg and 100 mg mirodenafil 
ODF groups showed increases in the mean response 
rate of 43.46% and 41.22%, respectively, after treatment. 
Compared with the results of previous studies on con-
ventional tablets, the results of mirodenafil ODF 50 mg 
were similar, whereas ODF 100 mg showed a slightly 
smaller increase [5-8].
In this study, the mirodenafil ODF was shown to 
have slightly lower efficacy than conventional tablets 
in terms of IIEF-5 and SEP3 improvement. One of the 
reasons for this finding could be that the proportion of 
individuals with moderate to severe ED in our study 
was relatively higher than that in previous mirode-
nafil trials [5-8]. However, unlike the present study, a 
study investigating a sildenafil ODF and conventional 
tablets showed similar efficacy and safety for both 
agents [15].
Some limitations of the present study should be not-
ed.
First, although this study is the first on a mirode-
nafil ODF formulation, it is not a direct comparison 
with conventional tablets. Therefore, it was not pos-
sible to perform a direct comparison of the differences 
in efficacy, safety, and satisfaction between the two 
formulations.
Second, with regard to the changes in IIEF-5 (the pri-
mary efficacy variable), the mirodenafil 50 mg treat-
ment group showed a greater improvement than the 
placebo group, but the changes were not statistically 
significant. This was considered to be attributed to the 
high participation rate of patients with severe ED, who 
did not improve sufficiently with the lower dose of 
mirodenafil.
Third, a relatively short study treatment period of 8 
weeks was used. Fourth, owing to sociocultural differ-
ences among various populations of different ethnic 
origins, the efficacy and safety profile of mirodenafil 
observed in this study, which included Korean patients 
only, may not be similar to that in other ethnic groups.
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CONCLUSIONS
Mirodenafil ODF 50 mg and 100 mg, taken as needed 
before sexual activity during an 8-week study period, 
resulted in significant improvements in erectile func-
tion, as measured by the IIEF-5, SEP, GAQ, and LSC 
scores in patients with ED. Moreover, the frequency 
and severity of adverse events were low, indicating 
that the mirodenafil ODF was safe and well tolerated. 
The mirodenafil ODF may be a good choice to comple-
ment conventional tablets and increase the therapeutic 
compliance of patients taking PDE5 inhibitors.
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